AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

AbbVie (NYSE: ABBV) and Boehringer Ingelheim's Skyrizi performed better than Novartis' (NYSE: NVS) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an autoimmune skin disease.